Thierry André
Impact in
- Oncology top 0.01%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Pathology and Forensic Medicine top 0.05%
- Genetic factors in colorectal cancer
Papers in
- Oncology 339
- Colorectal Cancer Treatments and Studies 254
- Colorectal Cancer Surgical Treatments 65
- Cancer Treatment and Pharmacology 45
- Cancer Immunotherapy and Biomarkers 42
-
- Genetic factors in colorectal cancer 121
- Co-authors
- Aimery de Gramont (117 shared papers)Christophe Louvet (92 shared papers)Josep M. Tabernero (28 shared papers)Christophe Tournigand (60 shared papers)Tamas Hickish (9 shared papers)Corrado Boni (6 shared papers)John Bridgewater (3 shared papers)C. Topham (3 shared papers)
- Journals
- Annals of Oncology (96 papers)Journal of Clinical Oncology (50 papers)European Journal of Cancer (43 papers)The Lancet Oncology (15 papers)Clinical Colorectal Cancer (14 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Thierry André
533 papers receiving 42.4k citations
Thierry André's Hit Papers
Peers
Comparison fields: 5 of 186
- Oncology 27.4k
- Pathology and Forensic Medicine 7.7k
- Hepatology 3.1k
- Cancer Research 4.7k
- Pulmonary and Respiratory Medicine 7.3k
Countries citing papers authored by Thierry André
This map shows the geographic impact of Thierry André's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry André with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry André more than expected).
Fields of papers citing papers by Thierry André
This network shows the impact of papers produced by Thierry André. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry André. The network helps show where Thierry André may publish in the future.
Co-authors
The 25 scholars most cited alongside Thierry André, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 558 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer Hit paper breakdown → | 2004 | 3002 |
| 2 | FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study Hit paper breakdown → | 2003 | 2480 |
| 3 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Hit paper breakdown → | 2017 | 2279 |
| 4 | Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer Hit paper breakdown → | 2020 | 2153 |
| 5 | Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial Hit paper breakdown → | 2009 | 1804 |
| 6 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Hit paper breakdown → | 2018 | 1672 |
| 7 | KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Hit paper breakdown → | 2008 | 1249 |
| 8 | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Hit paper breakdown → | 2012 | 962 |
| 9 | Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2010 | 824 |
| 10 | Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib Hit paper breakdown → | 2016 | 818 |
| 11 | Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial Hit paper breakdown → | 2005 | 818 |
| 12 | Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Hit paper breakdown → | 2019 | 766 |
| 13 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer Hit paper breakdown → | 2018 | 748 |
| 14 | OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study Hit paper breakdown → | 2006 | 660 |
| 15 | Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study Hit paper breakdown → | 2022 | 649 |
| 16 | 2005 | 597 | |
| 17 | Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study Hit paper breakdown → | 2015 | 540 |
| 18 | 2009 | 533 | |
| 19 | Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer Hit paper breakdown → | 2018 | 492 |
| 20 | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer Hit paper breakdown → | 2019 | 485 |
About Thierry André
Thierry André is a scholar working on Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 558 papers that have together received 43.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (254 papers), Genetic factors in colorectal cancer (121 papers), Colorectal Cancer Surgical Treatments (65 papers), Gastric Cancer Management and Outcomes (57 papers), Cancer Treatment and Pharmacology (45 papers), Cancer Immunotherapy and Biomarkers (42 papers), Colorectal and Anal Carcinomas (42 papers) and Cancer Genomics and Diagnostics (35 papers). The work is most often cited by research in Oncology (27.4k citations), Pathology and Forensic Medicine (7.7k citations), Hepatology (3.1k citations), Cancer Research (4.7k citations) and Pulmonary and Respiratory Medicine (7.3k citations). Thierry André has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Aimery de Gramont, Christophe Louvet, Josep M. Tabernero, Christophe Tournigand, Tamas Hickish, Corrado Boni, John Bridgewater, C. Topham, Matilde Navarro and Philip R. Clingan. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, The Lancet Oncology and Clinical Colorectal Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.